Third Harmonic Bio to Participate in the Jefferies Global Healthcare Conference
Third Harmonic Bio (Nasdaq: THRD), a clinical-stage biopharmaceutical company, announced that its CEO, Natalie Holles, will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 5, 2024, at 7:30 a.m. ET.
The event will be webcast live on the Third Harmonic Bio website, with a replay available for 90 days post-event.
The company focuses on developing treatments for dermal, respiratory, and gastrointestinal inflammatory diseases.
- Participation in the Jefferies Global Healthcare Conference enhances visibility and credibility within the industry.
- CEO Natalie Holles' involvement provides an opportunity for direct communication with investors and stakeholders.
- Webcast availability and 90-day replay period increase access for interested parties, potentially broadening investor base.
- No new financial data or clinical trial updates were provided in the PR, offering new actionable information for investors.
- The announcement does not address any current challenges or risks the company may be facing.
SAN FRANCISCO, May 28, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a clinical-stage biopharmaceutical company focused on advancing the next wave of medicine for dermal, respiratory, and gastrointestinal inflammatory diseases, today announced that Chief Executive Officer, Natalie Holles, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 5, 2024, at 7:30 a.m. ET.
A live audio webcast will be available within the Investors & Media section of the Third Harmonic Bio website. An archived replay will be accessible for 90 days following the event.
About Third Harmonic Bio, Inc.
Third Harmonic Bio is a clinical stage biopharmaceutical company focused on advancing the next wave of medicine for dermal, respiratory, and gastrointestinal inflammatory diseases through the development of novel, highly selective, small-molecule inhibitors of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. Early clinical studies demonstrate that KIT inhibition has the potential to revolutionize the treatment of a broad range of mast-cell-mediated inflammatory diseases, and that a titratable, oral small molecule inhibitor may provide the optimal therapeutic profile against this target. Third Harmonic Bio’s lead product candidate, THB335, is a titratable, oral, small molecule inhibitor that is currently in a Phase 1 clinical trial. For more information, please visit the Third Harmonic Bio website: www.thirdharmonicbio.com.
Investor and Media Contact:
Lori Murray
lori.murray@thirdharmonicbio.com
FAQ
When will Third Harmonic Bio participate in the Jefferies Global Healthcare Conference?
Who will represent Third Harmonic Bio at the Jefferies Global Healthcare Conference?
How can I access the Third Harmonic Bio webcast from the Jefferies Global Healthcare Conference?
What is the focus of Third Harmonic Bio's research and development?
What is the stock symbol for Third Harmonic Bio?
